Vasopressin antagonists
| Autor: | R, Lemmens-Gruber, M, Kamyar |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Pharmacology
Clinical Trials as Topic Binding Sites Indoles Pyrrolidines Vasopressins Water-Electrolyte Imbalance Azepines Cell Biology Benzazepines Cellular and Molecular Neuroscience Hormone Antagonists Cardiovascular Diseases Benzamides Tolvaptan Animals Humans Molecular Medicine Pyrroles Molecular Biology Antidiuretic Hormone Receptor Antagonists |
| Zdroj: | Cellular and Molecular Life Sciences. 63:1766-1779 |
| ISSN: | 1420-9071 1420-682X |
| DOI: | 10.1007/s00018-006-6054-2 |
| Popis: | Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension. As vasopressin receptors are found in many different tissues, vasopressin antagonists may benefit the treatment of disorders such as cerebral ischaemia and stroke, Raynaud's disease, dysmenorrhoea and tocolytic treatment. V1b selective vasopressin antagonists are discussed in terms of their usefulness in the treatment of emotional and psychiatric disorders. The vaptans are vasopressin receptor antagonists with V1a (relcovaptan) or V2 (tolvaptan, lixivaptan) selectivity or non-selective activity (conivaptan) which may be advantageous in some disorders. The V1a/V2 non-selective vasopressin antagonist conivaptan is the first vaptan which is approved by the FDA for the treatment of euvolaemic hyponatraemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink